Eton Pharmaceuticals (ETON) Gross Profit (2019 - 2026)

Eton Pharmaceuticals has disclosed Gross Profit across 8 years of filings, most recently posting $25.4 million for Q2 2026.

• In Q2 2026, Gross Profit rose 113.12% year-over-year to $25.4 million; the TTM figure through Jun 2026 stood at $58.3 million (up 68.65% YoY), while the FY2025 annual figure was $42.7 million, up 82.56% from the prior year.
• Gross Profit came in at $25.4 million for Q2 2026 at Eton Pharmaceuticals, up from $13.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $25.4 million in Q2 2026 to a low of $1.3 million in Q1 2022.
• Average Gross Profit over 5 years is $7.5 million, with a median of $6.3 million recorded in 2024.
• The largest YoY upside for Gross Profit was 1567.77% in 2022 against a maximum downside of 87.13% in 2022.
• Over 5 years, Gross Profit stood at $6.4 million in 2022, then tumbled by 42.92% to $3.6 million in 2023, then jumped by 78.4% to $6.5 million in 2024, then soared by 102.29% to $13.1 million in 2025, then jumped by 93.99% to $25.4 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $25.4 million in Q2 2026, $13.1 million in Q4 2025, and $7.9 million in Q3 2025.